​WRIT Media Group, Inc. Announces Initiative to Increase Shareholder Communication

Spotlight News  |

WRIT Media Group, Inc.  (WRIT) ()is pleased to provide you with this corporate update to inform you of the commencement of our initiative to increase shareholder communication. Over the coming months, we plan to explore an array of communications tools; including social media, to further our means of interaction with our shareholders, supporters and our strategic partners. As part of this initiative, we ask you to please visit www.writmediagroup.com/newsletter-signup and sign up to receive future corporate updates and other pertinent corporate materials. We believe that this effort will better educate the market on the work we are doing to add value to the Company.

From our acquisition of Bison Oil & Gas, which includes approximately $80 million in oil and gas assets, to other new projects we are developing, Writ Media Group has lots of exciting news, making it important for us to establish efficient channels of communication with its shareholders and supporters. We intend to achieve this designated objective through two primary means: (1) organic development of our Pelecoin World mobile application; and (2) strategic alliances through carefully managed partnerships with well positioned public companies. As part of this strategy, we plan on rounding out our management team and developing an advisory board with strategic key opinion leaders in the fields of digital currency and liquid asset management.

WRIT Media Group looks forward to keeping you updated on our developments as we move forward and encourage you to sign up for future updates from the Company by clicking on the following link: www.writmediagroup.com/newsletter-signup

About WRIT Media Group

WRIT Media Group, Inc. (OTCQB: WRIT) is a diversified company whose operations include digital currency software development, including trading platforms, and Blockchain solutions, hosting solutions for crypto mining, oil and gas reserves, content production and distribution; and video game distribution via mobile platforms.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
WRIT WRIT Media Group Inc 0.07 -0.01 -6.67 7,050

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.